|The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
CHICAGO — In seeking to improve clinical trial enrollment at a large multisite cancer center, researchers conducted a restrospective review to compare clinical trial inquiries through Electronically Accessible Pathways (EAPathways) and clinical trial enrollment using Oncore between January 2017 and July 2018. Their findings that clinical pathways can provide access to trial enrollment across multiple settings were presented at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting.
The retrospective analysis found that 29.1% (740/2539) of inquiries via EAPathways resulted in a patient being enrolled in a clinical trial. The majority (67%) of enrollments were seen at the main cancer center compared with the regional facilities. At regional locations, 82.9% (233/281) of patients were enrolled from inquiry.
EAPathways is a web-based clinical pathways program at the Levine Cancer Institute that is integrated into the electronic medical record (EMR). EAPathways is utilized at all 23 sites across the cancer network, and it provides real-time updates regarding treatment and clinical trials. The program provides standard treatment options that are determined by a disease-specific team and reminds healthcare providers about access to services, including genomic testing, clinical trials, tobacco cessation programs, and molecular tumor boards.
Clinical trial enrollment is challenging for a variety of reasons, including study design and protocol, restrictive eligibility criteria, access barriers for patients, patient disparities, and the perception of clinical trials among patients.
“EAPathways empowers clinicians and provides access to clinical trial enrollment at regional sites,” concluded presenter Jeryl Jean Villadolid, PharmD, BCPS, BCOP, of the Levine Cancer Institute in Charlotte, North Carolina. “Ongoing collection of metrics through pathways will allow for process improvement and providers need efficiency tools to help deliver cutting-edge care.”
Disclosure: Multiple authors declared affiliations with industry. Please refer to the original abstract for a full list of disclosures.
Read more of Cancer Therapy Advisor‘s coverage of ASCO’s annual meeting by visiting the conference page.
Villadolid JJ, Jandrisevits E, Moore D, Patel JN, Mileham KF, Kim ES. Impact of Electronically Accessible Pathways (EAPathways) on clinical trial enrollment at a large multisite cancer center. Oral presentation at: 2019 ASCO Annual Meeting; May 31 to June 4, 2019; Chicago, IL. Abstract 6517.
This article originally appeared on Oncology Nurse Advisor